## VITROLIFE GROUP

## Vitrolife Group completes refinancing facility backed by leading Nordic Banks

Vitrolife AB (publ) has today renewed and signed a loan agreement of EUR 300 million comprising of term loan and revolving credit facility. The term loan will be used to refinance existing debt and the revolving credit facility will be available for general corporate purposes.

The loan agreement is backed by leading Nordic banks, with Nordea and SEB renewing their commitments and AB Svensk Exportkredit joining as a new lender, underscoring the Vitrolife Group's strong credit profile and focus on export. The loan agreement has a tenor of three-years and includes two one-year extension options.

"We appreciate the support from our existing and new banking partners in connection with this refinancing. This successful transaction underlines the confidence in the Vitrolife Group", says Bronwyn Brophy O'Connor, CEO of the Vitrolife Group.

Gothenburg, 1 July 2025 VITROLIFE AB (publ) Bronwyn Brophy O'Connor, CEO

## **Contact:**

Amelie Wilson, Investor relations, external corporate communications and executive support, awilson@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.